{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:01:17Z","timestamp":1785456077407,"version":"3.56.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) disrupts the gut microbiome through dietary restrictions, uraemia, and polypharmacy, including phosphate binders. This dysbiosis contributes to systemic inflammation, accumulation of uremic toxins, and reduced short-chain fatty acid (SCFA)-producing bacteria. Hyperphosphatemia, a key CKD complication, typically emerges in advanced stages. This review examines the impact of phosphate binders on gut microbiota and explores emerging biological therapies.<\/jats:p>\n                  <jats:p>Phosphate binders are standard treatment for hyperphosphatemia but may influence gut microbiota by altering luminal pH, intestinal transit, and availability of metabolites such as SCFAs and vitamin K. These changes can impair gut barrier integrity and promote inflammation. Evidence on their microbiome effects is mixed: some studies show minimal compositional changes with calcium acetate or sucroferric oxyhydroxide, while others report individual variability and subtle taxon-specific shifts, particularly with iron-based binders. Even when compositional changes are limited, certain binders may modulate uremic toxin levels.<\/jats:p>\n                  <jats:p>Given the limitations of conventional therapies, biological approaches such as probiotics, synbiotics, and phosphate-accumulating organisms (PAOs) are gaining interest. These strategies may reduce intestinal phosphate availability by lowering pH, enhancing calcium-phosphate binding, and promoting microbial phosphate uptake and storage, while supporting gut barrier function.<\/jats:p>\n                  <jats:p>Overall, current evidence remains heterogeneous and limited by small cohorts and preclinical designs. Although microbiota-targeted therapies show mechanistic promise, robust clinical trials are needed before they can be recommended beyond adjunctive use.<\/jats:p>","DOI":"10.1093\/joneph\/aajag023","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:14:45Z","timestamp":1769422485000},"page":"495-504","source":"Crossref","is-referenced-by-count":0,"title":["Phosphate binders and the gut microbiota in chronic kidney disease: mechanisms, mixed evidence, and\u00a0clinical considerations"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0782-2244","authenticated-orcid":false,"given":"Mansi","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mercy Health St. Vincent Medical Center , Toledo, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Babu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jaipur Golden Hospital , Rohini, Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Jain","sequence":"additional","affiliation":[{"name":"Consultant, Internal Medicine, Arihant Jain Clinic , Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026073019521993900_aajag023-B1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s12889-025-21851-z","article-title":"Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Public Health"},{"key":"2026073019521993900_aajag023-B2","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","article-title":"The major global burden of chronic kidney disease","volume":"12","author":"Jadoul","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026073019521993900_aajag023-B3","doi-asserted-by":"publisher","first-page":"172892","DOI":"10.1016\/j.ejphar.2019.172892","article-title":"Gut microbiota; an overlooked effect of phosphate binders","volume":"868","author":"Rahbar Saadat","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2026073019521993900_aajag023-B4","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.26355\/eurrev_202203_28354","article-title":"Link between gut microbiota dysbiosis and chronic kidney disease","volume":"26","author":"Noce","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026073019521993900_aajag023-B5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","journal-title":"Kidney Int"},{"key":"2026073019521993900_aajag023-B6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.akdh.2022.12.011","article-title":"Physiopathology of phosphate disorders","volume":"30","author":"Portales-Castillo","year":"2023","journal-title":"Adv Kidney Dis Health"},{"key":"2026073019521993900_aajag023-B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2026073019521993900_aajag023-B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.jrn.2019.01.004","article-title":"Phosphate binders and nonphosphate effects in the gastrointestinal tract","volume":"30","author":"Biruete","year":"2020","journal-title":"J Ren Nutr"},{"key":"2026073019521993900_aajag023-B9","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1053\/j.jrn.2022.12.004","article-title":"Targeting the gut microbiota in kidney disease: the future in renal nutrition and metabolism","volume":"33","author":"Lambert","year":"2023","journal-title":"J Ren Nutr"},{"key":"2026073019521993900_aajag023-B10","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/app13053212","article-title":"The gastrointestinal microbiota as a potential cause and target in chronic kidney disease accentuating treatment and intervention strategies","volume":"13","author":"Zupcic","year":"2023","journal-title":"Appl Sci"},{"key":"2026073019521993900_aajag023-B11","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/microorganisms12091878","article-title":"The role of the gut microbiota in complications among hemodialysis patients","volume":"12","author":"Du","year":"2024","journal-title":"Microorganisms"},{"key":"2026073019521993900_aajag023-B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40168-021-01024-x","article-title":"Intestinal mycobiota in health and diseases: from gut immunity to metabolism and beyond","volume":"9","author":"Wu","year":"2021","journal-title":"Microbiome"},{"key":"2026073019521993900_aajag023-B13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fcimb.2019.00206","article-title":"Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease.","volume":"9","author":"Li","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2026073019521993900_aajag023-B14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/nep.13245","article-title":"Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders: an in vitro study","volume":"24","author":"Schumacher","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"2026073019521993900_aajag023-B15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10157-020-01892-x","article-title":"Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis","volume":"24","author":"Iguchi","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"2026073019521993900_aajag023-B16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1159\/000517470","article-title":"Gut microbiome-derived uremic toxin levels in hemodialysis patients on different phosphate binder therapies","volume":"51","author":"Wang","year":"2022","journal-title":"Blood Purif"},{"key":"2026073019521993900_aajag023-B17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/nu13041273","article-title":"Phosphate, microbiota and CKD","volume":"13","author":"Favero","year":"2021","journal-title":"Nutrients"},{"key":"2026073019521993900_aajag023-B18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/sdi.13030","article-title":"Feeling gutted in chronic kidney disease (CKD): gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis","volume":"37","author":"Biruete","year":"2024","journal-title":"Semin Dial"},{"key":"2026073019521993900_aajag023-B19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000518110","article-title":"Small intestinal phosphate absorption: novel therapeutic implications","volume":"52","author":"Yee","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026073019521993900_aajag023-B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/toxins13020091","article-title":"Intestinal chelators, sorbants, and gut-derived uremic toxins","volume":"13","author":"Laville","year":"2021","journal-title":"Toxins (Basel)"},{"key":"2026073019521993900_aajag023-B21","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s11255-021-03091-3","article-title":"Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study","volume":"54","author":"Merino-Ribas","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2026073019521993900_aajag023-B22","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1002\/prp2.1187","article-title":"Lanthanum hydroxide protects kidney through gut microbiota in a rat model of chronic kidney disease","volume":"12","author":"Gao","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"2026073019521993900_aajag023-B23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/toxins12060351","article-title":"Sevelamer use in end-stage kidney disease (ESKD) patients associates with poor vitamin K status and high levels of gut-derived uremic toxins: a drug-bug interaction?","volume":"12","author":"Dai","year":"2020","journal-title":"Toxins (Basel)"},{"key":"2026073019521993900_aajag023-B24","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1038\/s41598-022-13552-z","article-title":"Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients","volume":"12","author":"Abdelbary","year":"2022","journal-title":"Sci Rep"},{"key":"2026073019521993900_aajag023-B25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/hdi.13187","article-title":"Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: a systematic review and meta-analysis","volume":"29","author":"Georgopoulos","year":"2025","journal-title":"Hemodial Int"},{"key":"2026073019521993900_aajag023-B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.32383\/farmpol\/147643","article-title":"Gut microbiota modulation in the chronic kidney disease management","volume":"78","author":"Dobrek","year":"2022","journal-title":"Farm Pol"},{"key":"2026073019521993900_aajag023-B27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/medicina59050959","article-title":"Understudied hyperphosphatemia (chronic kidney disease) treatment targets and new biological approaches","volume":"59","author":"Anand","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026073019521993900_aajag023-B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ckj\/sfs072","article-title":"Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis","volume":"5","author":"Ogawa","year":"2012","journal-title":"Clin Kidney J"},{"key":"2026073019521993900_aajag023-B29","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/s41598-025-91033-9","article-title":"Synbiotics as a novel therapeutic approach for hyperphosphatemia and hyperparathyroidism in chronic kidney disease rats","volume":"15","author":"Anegkamol","year":"2025","journal-title":"Sci Rep"},{"key":"2026073019521993900_aajag023-B30","doi-asserted-by":"publisher","first-page":"16485","DOI":"10.1038\/s41598-021-95176-3","article-title":"Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)","volume":"11","author":"Anand","year":"2021","journal-title":"Sci Rep"},{"key":"2026073019521993900_aajag023-B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.23876\/j.krcp.21.014","article-title":"The effect of probiotic supplementation on systemic inflammation in dialysis patients","volume":"41","author":"Choi","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"2026073019521993900_aajag023-B32","doi-asserted-by":"publisher","first-page":"8347","DOI":"10.1021\/acs.jafc.4c00263","article-title":"Exploring the preventive and therapeutic mechanisms of probiotics in chronic kidney disease through the gut-kidney axis","volume":"72","author":"Huang","year":"2024","journal-title":"J Agric Food Chem"},{"key":"2026073019521993900_aajag023-B33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026073019521993900_aajag023-B34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/ndt\/gfv095","article-title":"Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, and potential consequences","volume":"31","author":"Vaziri","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019521993900_aajag023-B35","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/495\/68335689\/aajag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/495\/68335689\/aajag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:29Z","timestamp":1785455549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/3\/495\/8687430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,19]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag023","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}